# Hypoxia, ROS, and HIF Signaling in I/R Injury: Implications and Future Prospects

**Authors:** Manish Kumar Singh, Hyeong Rok Yun, Jyotsna S. Ranbhise, Sunhee Han, Sung Soo Kim, Insug Kang

PMC · DOI: 10.3390/antiox15020153 · Antioxidants · 2026-01-23

## TL;DR

This paper reviews how hypoxia, HIF signaling, and mitochondrial dysfunction contribute to heart damage during ischemia-reperfusion injury and explores their implications for treatment.

## Contribution

The paper provides a comprehensive review of the interplay between hypoxia, HIF signaling, and mitochondrial dysfunction in ischemic heart disease.

## Key findings

- HIFs play a central role in maintaining oxygen homeostasis and reducing ischemic damage.
- Mitochondrial dysfunction and ROS production are key factors in I/R injury.
- Stabilization of HIFs promotes cardiomyocyte survival and mitochondrial integrity.

## Abstract

Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide. Myocardial ischemia–reperfusion injury (MIRI) is a significant contributor to cardiac tissue damage, resulting from an abrupt reduction in blood flow that leads to a reduction in the supply of oxygen and nutrients. The resulting hypoxia triggers severe cellular injury and impairs organ function. Hypoxia-inducible factors (HIFs) play a central role in maintaining oxygen homeostasis in mammalian tissues. As primary oxygen sensors, HIFs trigger the transcriptional activation of a wide range of genes that facilitate cellular adaptation to reduced oxygen availability and assist in minimizing ischemic damage. Mitochondria are particularly vulnerable to hypoxic stress and are a major source of reactive oxygen species (ROS) during I/R injury. Stabilization of HIFs has been shown to reduce loss of cardiomyocytes under these conditions, highlighting the importance of HIF-dependent pathways in preserving mitochondrial integrity and promoting cell survival. Collectively, these observations suggest that hypoxia, HIF signaling, and mitochondrial dysfunction are tightly interconnected processes in the pathogenesis of IHD. This review, therefore, focuses on the interaction between hypoxia-driven HIF responses and mitochondrial regulation, emphasizing their implications for therapeutic strategies in managing IHD.

## Linked entities

- **Diseases:** ischemic heart disease (MONDO:0024644)

## Full-text entities

- **Genes:** MTNR1B (melatonin receptor 1B) [NCBI Gene 4544] {aka FGQTL2, MEL-1B-R, MT2}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, PGK1 (phosphoglycerate kinase 1) [NCBI Gene 5230] {aka HEL-S-68p, MIG10, PGKA}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, ADORA2B (adenosine A2b receptor) [NCBI Gene 136] {aka ADORA2}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, SUMO1 (small ubiquitin like modifier 1) [NCBI Gene 7341] {aka DAP1, GMP1, OFC10, PIC1, SMT3, SMT3C}, MAOA (monoamine oxidase A) [NCBI Gene 4128] {aka BRNRS, MAO-A}, HDAC6 (histone deacetylase 6) [NCBI Gene 10013] {aka CPBHM, HD6, JM21, KDAC6, PPP1R90}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, Egln1 (egl-9 family hypoxia-inducible factor 1) [NCBI Gene 112405] {aka C1orf12, HIF-PH2, HPH-2, Hif-p4h-2, ORF13, Phd2}, PLN (phospholamban) [NCBI Gene 5350] {aka CMD1P, CMH18, PLB}, DNMT3B (DNA methyltransferase 3 beta) [NCBI Gene 1789] {aka FSHD4, ICF, ICF1, M.HsaIIIB}, MUL1 (mitochondrial E3 ubiquitin protein ligase 1) [NCBI Gene 79594] {aka C1orf166, GIDE, MAPL, MULAN, RNF218}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, MIR210 (microRNA 210) [NCBI Gene 406992] {aka MIRN210, mir-210}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, SIRT6 (sirtuin 6) [NCBI Gene 51548] {aka SIR2L6, hSIRT6}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, MTNR1A (melatonin receptor 1A) [NCBI Gene 4543] {aka MEL-1A-R, MT1}, PRX (periaxin) [NCBI Gene 57716] {aka CMT4F}, ARG1 (arginase 1) [NCBI Gene 383], BNIP3 (BCL2 interacting protein 3) [NCBI Gene 664] {aka HABON, NIP3}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, ETFDH (electron transfer flavoprotein dehydrogenase) [NCBI Gene 2110] {aka ETFQO, MADD}, Egln3 (egl-9 family hypoxia-inducible factor 3) [NCBI Gene 112407] {aka 2610021G09Rik, Hif-p4h-3, Phd3, SM-20}, EGLN3 (egl-9 family hypoxia inducible factor 3) [NCBI Gene 112399] {aka HIFP4H3, HIFPH3, PHD3}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, Pten (phosphatase and tensin homolog) [NCBI Gene 19211] {aka 2310035O07Rik, A130070J02Rik, B430203M17Rik, MMAC1, PTENbeta, TEP1}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, Bnip3 (BCL2 interacting protein 3) [NCBI Gene 84480], COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, SDHB (succinate dehydrogenase complex iron sulfur subunit B) [NCBI Gene 6390] {aka CWS2, IP, MC2DN4, PGL4, PPGL4, SDH}, SDHA (succinate dehydrogenase complex flavoprotein subunit A) [NCBI Gene 6389] {aka CMD1GG, FP, MC2DN1, NDAXOA, PGL5, PPGL5}, NCOA2 (nuclear receptor coactivator 2) [NCBI Gene 10499] {aka GRIP1, KAT13C, NCoA-2, SRC-2, SRC2, TIF2}, Atr (ataxia telangiectasia and Rad3 related) [NCBI Gene 245000], ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1) [NCBI Gene 953] {aka ATP-DPH, ATPDase, CD39, NTPDase-1, SPG64}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, NDUFV2 (NADH:ubiquinone oxidoreductase core subunit V2) [NCBI Gene 4729] {aka CI-24k, MC1DN7}, LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, GSR (glutathione-disulfide reductase) [NCBI Gene 2936] {aka CNSHA10, GR, GSRD, HEL-75, HEL-S-122m}, NQO1 (NAD(P)H quinone dehydrogenase 1) [NCBI Gene 1728] {aka DHQU, DIA4, DTD, NMOR1, NMORI, QR1}, SENP1 (SUMO specific peptidase 1) [NCBI Gene 29843] {aka SuPr-2}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CRELD1 (CRELD disulfide isomerase 1) [NCBI Gene 78987] {aka AVSD2, CIRRIN, JELANS}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, EGLN1 (egl-9 family hypoxia inducible factor 1) [NCBI Gene 54583] {aka C1orf12, ECYT3, HALAH, HIF-PH2, HIFPH2, HPH-2}
- **Diseases:** Hypoxia (MESH:D000860), intermittent claudication (MESH:D007383), vasospasm (MESH:D020301), iron (MESH:D000090463), stenosis (MESH:D003251), cardiotoxicity (MESH:D066126), ischemia (MESH:D007511), proteinuria (MESH:D011507), MDS (MESH:D009190), SCI (MESH:D013119), erythrocytosis (MESH:D011086), ICM (MESH:D009202), retinopathy (MESH:D058437), acute kidney injury (MESH:D058186), LVPO (MESH:D018487), obesity (MESH:D009765), hemorrhage (MESH:D006470), hypoxic (MESH:D002534), arrhythmias (MESH:D001145), CLI (MESH:D000089802), angina (MESH:D000787), pulmonary edema (MESH:D011654), Coronary spasm (MESH:D003329), lung injury (MESH:D055370), edema (MESH:D004487), CKD (MESH:D051436), dyspnea (MESH:D004417), kidney failure (MESH:D051437), cancer (MESH:D009369), AMIS (MESH:D002545), endothelial dysfunction (MESH:D014652), ischemic myocardium (MESH:D017682), valvular heart disease (MESH:D006349), diabetes (MESH:D003920), impaired visual function (MESH:D014786), dyslipidemia (MESH:D050171), hyperoxia (MESH:D018496), CHD (MESH:D003327), Mitochondrial Dysfunction (MESH:D028361), chronic inflammation (MESH:D007249), neurodegeneration (MESH:D019636), cardiomyocyte injury (MESH:D014947), metabolic syndrome (MESH:D024821), cardiomyocyte loss (MESH:D016388), fibrosis (MESH:D005355), Calcium overload (MESH:D019190), renal cell carcinoma (MESH:D002292), tissue injury (MESH:D017695), apoptosis (MESH:D065703), pulmonary hypertension (MESH:D006976), diabetic nephropathy (MESH:D003928), cardiomyocyte necrosis (MESH:D009336), RCM (MESH:D002313), HCM (MESH:D002312), cardiac remodeling (MESH:D020257), IRI (MESH:D015428), cardiac disorders (MESH:D006331), CAD (MESH:D003324), embolism (MESH:D004617), T2DM (MESH:D003924)
- **Chemicals:** cholesterol (MESH:D002784), NO (MESH:D009569), Ketone bodies (MESH:D007657), aldehyde (MESH:D000447), DMOG (MESH:C040947), blood glucose (MESH:D001786), resveratrol (MESH:D000077185), norepinephrine (MESH:D009638), 4-HNE (MESH:C027576), enarodustat (MESH:C000656654), iron (MESH:D007501), daprodustat (MESH:C000599718), MitoQ (MESH:C429014), acetylcholine (MESH:D000109), canagliflozin (MESH:D000068896), PT2977 (MESH:C000720612), FG-4592 (MESH:C584543), vadadustat (MESH:C000624313), cardiolipins (MESH:D002308), Metformin (MESH:D008687), ketone (MESH:D007659), CoQ10 (MESH:C024989), epinephrine (MESH:D004837), lipid peroxides (MESH:D008054), TCA (MESH:D014233), molidustat (MESH:C000603972), PCA (MESH:C005581), lactate (MESH:D019344), beta-Sitosterol (MESH:C025473), DT (MESH:C000713095), diltiazem (MESH:D004110), Asiatic acid (MESH:C017032), molecular oxygen (MESH:D010100), Succinate (MESH:D019802), adenosine (MESH:D000241), Elamipretide (MESH:C506540), pyruvate (MESH:D019289), beta-hydroxybutyrate (MESH:D020155), Pro (MESH:D011392), serotonin (MESH:D012701), glucose (MESH:D005947), ROS (MESH:D017382), saponins (MESH:D012503), calcium (MESH:D002118), BBR (MESH:D001599), NADH (MESH:D009243), SEV (MESH:D000077149), 3'-MOP (MESH:C517305), H+ (MESH:D006859), lipid (MESH:D008055), ATP (MESH:D000255), AMP (MESH:D000249), GSH (MESH:D005978), acetoacetate (MESH:C016635), VP16 (MESH:D005047), GSSG (MESH:D019803), fatty acid (MESH:D005227), MDA (MESH:D008315), acetone (MESH:D000096), NMN (MESH:D009537)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Porifera (sponges, phylum) [taxon 6040], Ctenophora (genus) [taxon 1003038], Ctenophora (coelenterates, phylum) [taxon 10197], Panax notoginseng (notoginseng, species) [taxon 44586], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** C > T, A2A, Ala16Val, rs350846, rs1050450, G>A, rs28365927, rs2057482
- **Cell lines:** PC12 — Rattus norvegicus (Rat), Rat adrenal gland pheochromocytoma, Cancer cell line (CVCL_0481)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938460/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938460/full.md

## References

317 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938460/full.md

---
Source: https://tomesphere.com/paper/PMC12938460